Xenetic Biosciences, Inc.
News
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Accesswire FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ('Xenetic' or the 'Company'), a biopharmaceutical company focused on advancing innovative immune-oncology...\n more…
Q3 2024 EPS Estimates for Xenetic Biosciences Inc (NASDAQ:XBIO) Lifted by Analyst
Ticker Report Xenetic Biosciences Inc (NASDAQ:XBIO - Free Report) - Stock analysts at HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for Xenetic Biosciences in a research note issued to...\n more…
Xenetic Biosciences (NASDAQ:XBIO) Receives "Neutral" Rating from HC Wainwright
Ticker Report HC Wainwright restated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO - Free Report) in a research note published on Tuesday morning, Benzinga reports. Xenetic Biosciences Trading...\n more…
Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Simply Wall St Xenetic Biosciences ( NASDAQ:XBIO ) Second Quarter 2024 Results Key Financial Results Revenue: US$726.4k (up 12% from...\n more…
Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Meets Estimates
Ticker Report Xenetic Biosciences (NASDAQ:XBIO - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.83) earnings per share (EPS) for the quarter, hitting the consensus...\n more…
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Accesswire Ongoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with...\n more…